Heterocyclic Compounds

Matches 151 - 200 out of 8,193	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2023/120358A1	PRODUCTION METHOD FOR COMPOUND The present invention addresses the problem of providing a production method with which a condensed ring compound can be obtained at good yield. The present invention relates to a production method for a compound (II) represented by form...
WO/2023/118092A1	PYRAZOLO[1,5-A]PYRIDO[3,2-E]PYRIMIDINES AND PYRAZOLO[1,5-A][1,3]THIAZOLO[5,4-E]PYRIMIDINES AS P2X3 INHIBITORS FOR THE TREATMENT OF NEUROGENIC DISORDERS The present invention relates to substituted pyrazolo[l,5-a]pyridine-[3,2-e]pyrimidines compounds of formula (I) wherein X, R1, and R2 are as defined in the claims, methods of preparing said compounds, pharmaceutical compositions and com...
WO/2023/122298A1	PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS This invention provides protein stabilizing compounds that have a USP28 Targeting Ligand or USP25 Targeting Ligand, a Protein Targeting Ligand, and optionally a Linker, wherein the Target Protein is ubiquitinated. The protein stabilizing...
WO/2023/116866A1	FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF A five- and six-membered compound, and a preparation method therefor and a pharmaceutical composition and the use thereof. The five- and six-membered compound is a compound as shown in formula I, II or III. The compound has an inhibitory...
WO/2023/120359A1	COMPOUND AND PHOTOELECTRIC CONVERSION ELEMENT USING SAME The present invention addresses the problem of providing a compound which reduces the dark current.　The present invention relates to a compound which is represented by formula (I). (I): A1-P-A2 (In formula (I), each of A1 and A2 indepe...
WO/2023/119210A1	NOVEL COMPOUND AS RIPK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME The present invention relates to a compound as an RIPK1 inhibitor, a stereoisomer thereof, a tautomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and a pharmaceutical composition comprisi...
WO/2023/114954A1	PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS Provided herein are compounds and pharmaceutical compositions thereof for modulating SHP2 and their use in the treatment of disease.
WO/2023/110869A1	MICROBIOCIDAL BICYCLE HETEROCYCLIC DERIVATIVES A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
WO/2023/109912A1	3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF Provided are compounds as well as their compositions and methods of use. The compounds disclosed herein modulate, eg., antagonize, stimulator of interferon genes (STING) activity and are useful in the treatment of various inflammatory di...
WO/2023/108602A1	INTERMEDIATE OF EDOXABAN TOSYLATE AND PREPARATION METHOD THEREFOR Disclosed are an intermediate of edoxaban tosylate and a preparation method therefor, having the advantages that the preparation process is simple, reaction conditions are mild, the cost is low, and raw materials are easy to obtain. The ...
WO/2023/109158A1	7-METHYLTHIAZOLO[5,4-D]PYRIMIDINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention is a 7-methylthiazolo[5,4-d]pyrimidine compound, and a preparation method therefor and the use thereof. The compound comprises a compound represented by formula (I) or a physiologically acceptable salt ...
WO/2023/110138A1	INHIBITORS OF TRANSGLUTAMINASES The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
WO/2023/114822A1	BENZOTHIAZOLE, BENZOISOXAZOLE AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
WO/2023/104209A1	METTL3 INHIBITOR COMPOUND Provided are a class of METTL3 inhibitor compounds and a use thereof in preparation of a medication for inhibiting METTL3, thereby providing a new option for clinically selecting and/or preparing a medication for a disease related to MET...
WO/2023/103898A1	COMPOUND HAVING CLK AND DYRK INHIBITORY ACTIVITIES, PREPARATION METHOD THEREFOR AND USE THEREOF Provided is a novel compound having a macrocyclic structure. Specifically, provided are a compound having a macrocyclic structure of formula (I), or a pharmaceutically acceptable salt or a deuterated form thereof, and a method for prepar...
WO/2023/106405A1	COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, AND ORGANIC ELECTRONIC DEVICE Provided is a compound which can be advantageously used as an organic semiconductor material and has satisfactory solubility in solvents. An organic semiconductor material including such compound is provided. An organic electronic device...
WO/2023/104195A1	PREPARATION METHOD FOR ISOTHIAZOLO[5,4-D]PYRIMIDINE IRAK4 INHIBITOR Provided is a preparation method for an isothiazolo[5,4-d]pyrimidine IRAK4 inhibitor, particularly relating to a preparation method for the compound of formula (I) and an intermediate compound 6 thereof. The method for obtaining the tran...
WO/2023/107723A2	METHODS FOR TREATING NEUROLOGICAL DISORDERS This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, di...
WO/2023/098740A1	ORGANIC ROOM-TEMPERATURE ELECTROPHOSPHORESCENT MATERIAL, AND PREPARATION METHOD THEREFOR AND ORGANIC ELECTROLUMINESCENT DIODE THEREOF The present invention belongs to the technical field of photoelectric materials, and particularly relates to an organic room-temperature electrophosphorescent material, and a preparation method therefor and an organic electroluminescent ...
WO/2023/100942A1	COMPOUND FOR PHOTOOXYGENATION CATALYST AND MEDICINAL COMPOSITION CONTAINING SAME [Problem] To develop an artificial catalyst capable of inhibiting aggregation of pathogenic amyloids (tau amyloids) formed by the aggregation of tau proteins, and to provide a prophylactic and therapeutic medicine for amyloid-related dis...
WO/2023/100844A1	COMPOUND AND PHOTOELECTRIC CONVERSION ELEMENT EMPLOYING SAME The present invention addresses the problem of reducing a dark current.　The present invention relates to a compound represented by formula (I). (I): A1―P―A2 (In formula (I), each of A1 and A2 is independently an electron-withdrawin...
WO/2023/102507A1	MACROCYCLIC IMMUNOMODULATORS In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-I and are capable of inhibiting the interaction of PD-I with PD-LI. These macrocyclic compounds exhibit in vitro immunomodulatory effic...
WO/2023/097194A2	THERAPEUTIC COMPOUNDS AND METHODS OF USE This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
WO/2023/094830A1	SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein Ring A, Ring B, R1, R2, R3 and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion ch...
WO/2023/093700A1	IMIDAZOTHIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Disclosed are an imidazothiazole derivative, a preparation method therefor, and an application thereof. The imidazothiazole derivative has a structure represented by formula (I): R1 and R3 are each independently selected from optionally ...
WO/2023/088894A1	MACROCYCLIC 2-AMINO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1 The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
WO/2023/083365A1	PAD4 INHIBITORS AND USE THEREOF The present disclosure provides a compound represented by structural formula (I0) or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with the PAD4 activity. T...
WO/2023/087027A1	THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.
WO/2023/086341A1	INHIBITORS OF KRAS Disclosed herein are macrocyclic compounds that inhibit the binding of KRas. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the KRas inhibitors are disclosed, alone or in combination with othe...
WO/2023/081859A1	TRIAZINE AMINO DERIVATIVES FOR TREATING SCA3 Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
WO/2023/081858A1	CONDENSED-PYRAZINE AMINE DERIVATIVES FOR TREATING SCA3 Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
WO/2023/081637A1	FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositio...
WO/2023/081290A1	INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS Provided herein are compounds that modulate the activity of melanoma inhibitor of apoptosis (ML-IAP) protein, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
WO/2023/081857A1	CONDENSED PYRIDAZINE AMINE DERIVATIVES TREATING SCA3 Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
WO/2023/081441A1	HETEROCYCLIC COMPOUNDS AND USES THEREOF The present disclosure relates to compounds of Formula (I): (I), wherein Ring A, R1, R2, R3, and m are described herein. The present disclosure relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts, hy...
WO/2023/081860A1	TRIAZINE AMINO DERIVATIVES FOR TREATING SCA3 Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
WO/2023/078127A1	MACROCYCLIC SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF A macrocyclic sulfonamide compound, a preparation method therefor, and a medical use thereof. The macrocyclic sulfonamide compound has a specific structure as represented by formula (I). The macrocyclic sulfonamide compound or a pharmace...
WO/2023/072974A1	TRICYCLIC HETEROCYCLES The present invention relates to tricyclic heterocycles. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of...
WO/2023/074847A1	NOVEL SPIRO COMPOUND The present invention provides: a novel spiro compound having a TRH-DE inhibition activity and useful for the prevention/treatment of various diseases associated with TRH and/or symptoms associated with the diseases, or a pharmacological...
WO/2023/072292A1	EFFICIENT ANTIVIRAL COMPOUND AND USE THEREOF A compound as shown in the following formula (I-0) or a hydrate, solvate, optical isomer, polymorph, isotope derivative, pharmacologically acceptable salt thereof and a preparation method therefor. The compound can be used for preparing ...
WO/2023/068017A1	ORGANIC SEMICONDUCTOR MATERIAL The present invention provides: a polymer compound for providing an organic semiconductor material having excellent conversion efficiency; a starting material compound having a high degree of freedom in material design; and methods for m...
WO/2023/068881A1	ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES The present invention relates to an aryl or heteroaryl derivative and a pharmaceutical composition comprising same as an active ingredient, the aryl or heteroaryl derivative and the pharmaceutical composition being for the treatment of k...
WO/2023/060489A1	10-SUBSTITUTED-1-AZAPHENOTHIAZINE DERIVATIVE AND APPLICATION THEREOF A 10-substituted-1-azaphenothiazine derivative and an application thereof. The structure of the derivative is as represented by formula (I), and the definitions of respective substituents are as described in the description and the claim...
WO/2023/064152A1	TRICYCLIC SULFAMIDES AND SULTAMS Compounds of formula I, that modulate DCAF15 and induce RBM39 protein degradation, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with RBM39 protein activity ...
WO/2023/064879A1	COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
WO/2023/063249A1	COMPOUND, COMPOSITION FOR ANISOTROPIC DYE FILM COMPRISING SAID COMPOUND, ANISOTROPIC DYE FILM, AND OPTICAL ELEMENT A compound which is represented by formula (1). (1): X-A1-(N=N-A2)n-N=N-A3-Y (-A1- and -A2- are a divalent group from a possibly substituted polycyclic aromatic heterocycle that contains at least one S atom, or a divalent group from a po...
WO/2023/059899A1	FUSED BICYCLIC SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF The present application discloses novel compounds, pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a compound of the d...
WO/2023/041756A1	NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION The invention provides novel compounds having the general formula (I) wherein R1, R2, R3a, R3b, R4, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, and L are as described herein, compositions including the compounds and methods of using the comp...
WO/2023/043923A1	CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.
WO/2023/044171A1	INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF The disclosure provides compounds with nitrile warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with nitrile warheads are prov...

Matches 151 - 200 out of 8,193	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >